We are live on ! Find out more
HALO icon

Halozyme

367 hedge funds and large institutions have $5.65B invested in Halozyme in 2022 Q2 according to their latest regulatory filings, with 85 funds opening new positions, 127 increasing their positions, 113 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

370% more call options, than puts

Call options by funds: $24.6M | Put options by funds: $5.24M

227% more first-time investments, than exits

New positions opened: 85 | Existing positions closed: 26

80% more funds holding in top 10

Funds holding in top 10: 59 (+4)

16% more funds holding

Funds holding: 316367 (+51)

13% more capital invested

Capital invested by funds: $5.02B → $5.65B (+$629M)

12% more repeat investments, than reductions

Existing positions increased: 127 | Existing positions reduced: 113

0.16% less ownership

Funds ownership: 93.19%93.03% (-0.16%)

Holders
367
Holders Change
+51
Holders Change %
+16.14%
% of All Funds
6.18%
Holding in Top 10
9
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+80%
% of All Funds
0.15%
New
85
Increased
127
Reduced
113
Closed
26
Calls
$24.6M
Puts
$5.24M
Net Calls
+$19.4M
Net Calls Change
+$1.23M

HALO Hedge Fund Activity: Q2 2022 in Review

367 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q2 2022, worth a combined $5.65B — up 13% from $5.02B a quarter earlier.

Buyers outnumbered sellers: 85 funds opened new HALO positions and 26 closed out — a net gain of 59 holders — while 127 added to existing stakes and 113 trimmed.

The largest buyer was Victory Capital Management, adding an estimated $52.2M. The largest seller was Artisan Partners, cutting an estimated $126M.

  • 367 institutional investors held Halozyme (HALO) as of Q2 2022, up from 316 in Q1 2022.
  • Funds reported $5.65B of Halozyme stock for Q2 2022, up 13% quarter-over-quarter.
  • 85 funds opened new Halozyme positions in Q2 2022 and 26 closed out, a net change of +59 holders.
  • The largest Halozyme buyer in Q2 2022 was Victory Capital Management, an estimated $52.2M added.
  • The largest Halozyme seller in Q2 2022 was Artisan Partners, an estimated $126M sold.

Based on aggregated 13F filings for Q2 2022.